T2Sepsis Solution

Faster and more accurate testing for the detection of sepsis-causing pathogens than previously possible

T2 Magnetic Resonance (T2MR®) technology from T2 Biosystems is transforming diagnostics. T2MR works by measuring how water molecules react in the presence of magnetic fields, utilizing the same magnetic resonance-based approach found in MRI, but on a miniaturized scale. The advantage of T2MR, based on results from the proven T2Candida® Panel, is clear: highly accurate results with a sensitivity greater than 90% are available in just hours, not days.1

The only diagnostic requiring no blood culture proven to enhance patient care and hospital economics. 

Proven to deliver better patient care and greater cost savings

Powered by T2MR, the FDA-cleared T2Dx® Instrument and T2Candida Panel target Candida, one of the deadliest sepsis-causing pathogens. In fact, it is known to have a staggering 40% mortality rate, and costs the healthcare system an average of $130,000 per patient.2,3 The T2Dx Instrument and the T2Candida Panel are currently available in approximately 130 hospitals in the United States and Europe. Its impact is growing every day – here are some of the highlights:

  • Based on actual length-of-stay data, Henry Ford Hospital System in Michigan demonstrated that it was able to treat patients faster and more effectively with antifungal therapy, thereby projecting $2.3 million in total cost savings annually.4  

  • By implementing the T2Candida Panel, Lee Health System in Florida reduced length of stay (LOS) by an average of 7 days, while also decreasing the use of unnecessary antifungals, ultimately achieving net savings of about $200 per patient.5

 

  • Riverside Hospital in California was able to place 100% of patients who tested positive for sepsis-causing Candida on appropriate treatment within nine hours. None of these patients with an infection had even been considered for necessary antifungals prior to the T2Candida test.6

  • Huntsville Hospital in Alabama detected 56% more positive Candida patients than with standard blood culture. And for its negative patients, the hospital saved ~$500 per patient in medication costs due to the reduction in duration of drug therapy.7

Expanding the T2Sepsis Solution to include T2Bacteria®

We are expanding our T2Sepsis Solution to include the T2Bacteria Panel, which is tracking for FDA submission in mid-2017. T2Bacteria RUO Panel is currently available for Research Use Only (RUO) in the US.

Thanks to the aggressive efforts of clinicians and hospitals, about 60% of symptomatic patients today are on the appropriate antimicrobial therapy within the critical 24-hour window. But the limitations of current diagnostic technology leave about 40% of patients waiting too long for the right diagnosis and treatment.

The combined results from the T2Candida and T2Bacteria Panels—along with empiric antimicrobial therapy—will enable up to 95% of patients to receive effective therapy within those first critical 12 hours.

Sepsis – a serious public health crisis

Sepsis is one of the greatest challenges facing hospitals today. Sepsis contributes to nearly one in two hospital deaths.8 In fact, it is the most expensive hospital-treated condition in the U.S., representing $23.7B in U.S. healthcare costs,9 and it is the most frequent cause of hospital readmissions.10 The UK sees 147,000 cases diagnosed each year, contributing to 42,000 deaths11 and £2 billion in sepsis-related costs.12 It is their #2 killer after cardiovascular disease and claims more lives than lung cancer annually.13

Treating patients at risk of sepsis effectively—a major unmet need in healthcare

There are over 100 drugs that combat sepsis-causing pathogens; the greatest challenge for clinicians is to quickly identify the sepsis-causing pathogen and administer targeted treatment. The underlying problem? All current diagnostics rely on blood culture. However, culturing blood takes up to 5 days and misses up to half of infections.14 When nearly half of patients are missed in the critical first step, even the most accurate downstream blood-culture-reliant diagnostics cannot detect what blood culture missed.

No-blood-culture detection—the future of sepsis diagnostics is here today

Research has shown that the mortality rate for sepsis, if left unmanaged, rises by 8% every hour.15 Information to help clinicians target treatment in hours, not days, is the key to making a real difference in outcomes for patients with sepsis.

At T2, our mission is to save lives and improve healthcare. We believe that having the greatest impact on patients and their families requires a new approach that detects sepsis-causing pathogens directly from whole blood, without a blood culture. That’s what we set our minds to accomplish nearly a decade ago – and that’s exactly what we have done. Our T2Candida Panel is the only FDA-cleared diagnostic that can detect sepsis-causing pathogens without a blood culture.

……………………………………….

1. Mylonakis, E., Clancy, C. J., Ostrosky-Zeichner, L., Garey, K. W., Alangaden, G. J., Vazquez, J. A., … & Zervou, F. N. (2015). T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. Clinical Infectious Diseases, ciu959.
2. Parkins, M. D., et al. (2007). Journal of Antimicrobial Chemotherapy, 60(3), 613-618.
3. Gagne, J. J., Breitbart, R. E., Maio, V.,et. al. (2006). Costs associated with candidemia in a hospital setting. P and T, 31(10), 586.
4. Wilson, N.M., Kenney, R.M.,  Tibbetts, R.J., et. al.  T2 Magnetic Resonance Improves the Timely Management of Candidemia. Poster Presentation IDWeek 2016.
5. Estrada, S. J. Real World Value of T2Candida Lee Memorial Hospital. Slide Presentation ASM 2016.  
6. Patel F, Young E. Antifungal Prescribing During Initial Implementation of Candidemia Early Detection and Species Identification Testing with T2Candida Panel. Poster Presentation IDWeek 2016.
7. Kateon H et al. Utilization of T2Candida Panel for the rapid detection of Candida species in a large community hospital. Poster Presentation IDWeek 2016.
8. Liu, V., Escobar, G. J., Greene, J. D., Soule, J., Whippy, A., Angus, D. C., & Iwashyna, T. J. (2014). Hospital deaths in patients with sepsis from 2 independent cohorts. Jama, 312(1), 90-92.
9. Torio, C. M., Moore, B. J. (2016). Statistical Brief# 204. Healthcare Cost and Utilization Project (HCUP). May.
10. Mayr, F. B., Talisa, V. B., Balakumar, V., Chang, C. C. H., Fine, M., & Yende, S. (2017). Proportion and cost of unplanned 30-day readmissions after sepsis compared with other medical conditions. Jama, 317(5), 530-531.
11. Hex, Nick et al. The Cost of Sepsis Care in the UK. 2017.
12. Vincent, J., et al. “Sepsis in European intensive care units: results of the SOAP study.” Critical Care Medicine-Baltimore- 34.2 (2006): 344.
13. Daniels R. Surviving the first hours in sepsis: getting the basics right (an intensivist’s perspective). Journal of Antimicrobial Chemotherapy. 2011 Apr 1;66(suppl 2):ii11-23.
14. Clancy, C. J., & Nguyen, M. H. (2013). Finding the “missing 50%” of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clinical infectious diseases, 56(9), 1284-1292.
15. Kumar, A., Roberts, D., Wood, K. E., Light, B., Parrillo, J. E., Sharma, S., … & Gurka, D. (2006). Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Critical care medicine, 34(6), 1589-1596.